{"name":"Curium US LLC","slug":"curium-us-llc","ticker":"","exchange":"","domain":"curiumusllc.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Abiraterone with Prednisone or Enzalutamide","genericName":"Abiraterone with Prednisone or Enzalutamide","slug":"abiraterone-with-prednisone-or-enzalutamide","indication":"Metastatic castration-resistant prostate cancer (mCRPC)","status":"phase_3"},{"name":"Copper Cu 64 PSMA I&T","genericName":"Copper Cu 64 PSMA I&T","slug":"copper-cu-64-psma-i-t","indication":"Prostate cancer (imaging and therapeutic indication)","status":"phase_3"}]}],"pipeline":[{"name":"Abiraterone with Prednisone or Enzalutamide","genericName":"Abiraterone with Prednisone or Enzalutamide","slug":"abiraterone-with-prednisone-or-enzalutamide","phase":"phase_3","mechanism":"Abiraterone inhibits CYP17A1 to block androgen synthesis, while enzalutamide antagonizes the androgen receptor, together suppressing testosterone-driven prostate cancer growth; prednisone provides glucocorticoid support to mitigate mineralocorticoid excess from abiraterone.","indications":["Metastatic castration-resistant prostate cancer (mCRPC)","Non-metastatic castration-resistant prostate cancer (nmCRPC)"],"catalyst":""},{"name":"Copper Cu 64 PSMA I&T","genericName":"Copper Cu 64 PSMA I&T","slug":"copper-cu-64-psma-i-t","phase":"phase_3","mechanism":"Copper Cu 64 PSMA I&T is a radioactive diagnostic and therapeutic agent that binds to prostate-specific membrane antigen (PSMA) on cancer cells for imaging and treatment.","indications":["Prostate cancer (imaging and therapeutic indication)","PSMA-positive metastatic castration-resistant prostate cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPWjJJTTBUbHhvcF80b1kxVzhEZFRGMUR2Sm8zMWdib29ndS04OU5fWTEwRTZmQUFEeERQRGhGZk1HdzlhYWJMcHF0TENjcFJqLWR3bzduaml2OVRQMGRUczFLUWNYSHZvZFMxaHJMUEI5bENLcHZ2R1FyQW0wb013QWw5MHJfdw?oc=5","date":"2026-03-04","type":"pipeline","source":"WilmerHale","summary":"PTAB/USPTO Update - March 2026 - WilmerHale","headline":"PTAB/USPTO Update - March 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOZnFlQldRTDBLQ0ktbnF4MmE4WGs2T3R0VmpiaGVqcFRUalNQemljdFZEcWRNaFFoVzhMZW1TdmVsVFBmOGNFVHpWbUFzWDlzUVdUel9CeURTRldaUEZyeUcyUk9HVXluZjlTdmFoOFE2ZVNjRkp6QzN2WFl1SXlRWE5POVNfNGxhYk9OdXhLV2VYR2U3Z1F6ek84TEVXQXJVVGVLV2lJV1A4bTJQNjgyd0dRRkZZRzBXOWs1X2FOTjBJR19UcUF5Nkl3?oc=5","date":"2026-02-27","type":"regulatory","source":"IPWatchdog.com","summary":"Other Barks & Bites for Friday, February 27: UK Trademarks No Longer Within Scope of EU Law Post-Brexit; Second Circuit Reverses Ruling on Concert Rates Under BMI Consent Decree; USPTO Employee Pays $","headline":"Other Barks & Bites for Friday, February 27: UK Trademarks No Longer Within Scope of EU Law Post-Brexit; Second Circuit ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxONjJ2UzVYVEdMVTl2TWlRU05GMWJSeDh4U3h3MTRvRnNnWkFnR25tQ283d3VXcVdDenJGWFctOFFHNlRQSkRLU2R0Y05INjVMblZ2REkxd0ZwbS1ZVHE4VFhFSVVGTHkwVVZwM3VOZ05ad2xOc0VFRTNfdXFJRnhDU0JFcHFnSFhXVG9VWUlTYTVXRkRnY211MFc2Wnh3S1Qt0gFWQVVfeXFMTjY4eF9SaU9Sbkw2UkJJUm9aY05MRV9takF0ZDNxV0EwN3N0LTlHUTRJZTJZb1NxcnNnWTQxWm94Qzk3Njg1eUhfb19NN2E5dWNIdmpZRUE?oc=5","date":"2026-02-26","type":"pipeline","source":"Law360","summary":"Squires Grants 3 IPRs, Denies 10, Marks RPI Order Informative - Law360","headline":"Squires Grants 3 IPRs, Denies 10, Marks RPI Order Informative - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1nMTA5MHRoRENkUHFjSWt6NzRocmpWSnkyZG1USExyajUyOW9MU21qYzJFZXFEYzdBaFh6MkctSWppRzJDbTBaeWFILWpQcldoVzVVOER4eXQ5QVFseDdDQ0dxcFNmTHhXX2NTTFIzbHFRdlpuVlpGVw?oc=5","date":"2026-01-09","type":"regulatory","source":"NEREJ","summary":"Hunneman arranges 6,982 s/f sublease to Curium Pharma at at 2 Seaport Ln. - NEREJ","headline":"Hunneman arranges 6,982 s/f sublease to Curium Pharma at at 2 Seaport Ln.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQV3BKaWx0TWlVTFZ2Y2czZHlpOFFDdENiWHBXZVk0LVpxdkpKU3ZQMlFMSGhiOThPLWRISThsaHdkeFBFUlY1RWJKN294TW1XMENKMG1pWVFHTTdBTl8zVGRJZndhR0prSWJyWnYzNzhXdHlpeDd1VzJLeTNNWUFhZE0tNXRZWXhRdmcwSDhQeW1RWFFoS0tnTE90M1Bic0V2NDlmRUl0REZnMV9XZ1pfYUZhMlFDLVFSZnk2ZnhhNA?oc=5","date":"2025-12-30","type":"pipeline","source":"Forbes","summary":"U.S. Cold War Waste Reuse May Spur Nuclear Energy and Pharmaceuticals - Forbes","headline":"U.S. Cold War Waste Reuse May Spur Nuclear Energy and Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOUVpYRFFxd21QUTNQZll2V3UzZ3JvUzJXYzdfaUlqTTlMOU5hR3BGd0dFR0VDaXA3ZGZtTFJvUkhaRE5ieS1ON1JudXk3bzcwRjQzcmpNQ0gtc1dTLTl5cUZVVlBlQ3h1Z0E5bk5zdmVxQ1hnbE5LbUZ5cnZNSmJRN3owRUJGTi0yeWxza2pUNzhBWm8tT0JLcG9NNDlNUkM0NVQzbXhKUGxERlgxcHJ1QmppQmdSMDgtVV9lN3JUNExCNnc?oc=5","date":"2025-11-20","type":"pipeline","source":"PitchBook","summary":"CapVest sells Curium Pharma to continuation fund at $7B valuation - PitchBook","headline":"CapVest sells Curium Pharma to continuation fund at $7B valuation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPNFpobFZSbmJFbFlaVzlPVFdoZmRmYUI5XzRzc2RuNnRkSGVibUdTd0VORXpXU05FRjhhem1KTEVaa1hGU1VPRW85VURELWhmY01ia01XMkh4M0JNWWt4dVNFUnd3RjBBVWRzUGQ4TXpzU1VyTHhYTXdFZ19SQU1QeEI2aG1rRnVJT3ppQURyVVRObXhITjhDdWFVLVV3UkVsYmhrWmZCMFlZN2huUlc3b213?oc=5","date":"2025-11-18","type":"pipeline","source":"The Business Journals","summary":"Radiopharmaceutical firm Curium to expand St. Louis-area operations - The Business Journals","headline":"Radiopharmaceutical firm Curium to expand St. Louis-area operations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxPTlpBajMyYmxDWUVRSnpGNEIxODRVNWp3QnhNTmVlbDlYX3pld0NfN1ZHb09lU0lSVjJBMnd5cUpEMWZSU3VqUERJTXVoSS1rQmtHRFd4X1NjTGFkb1h6OTkwMmF0RUlFbHdrNENNUGtGampNYXlyQ2ZEUFBUdHYyT1ZfelVUTjRlem1yTEpWazRid3N4Nm5fbFRRTk5NMmU2dFJHRmZJUUY2UFFHUjUxel9nQkRhSjRtendtUndpb0QtUjk3VW5NUWFrZ1o2SHdWUVI1cmFuZnBsT2JGZVpPZHlkU3pVRUxnbk9jSURhdlhONUFjMTNyMFZRQndUaDQ?oc=5","date":"2025-11-17","type":"earnings","source":"GlobeNewswire","summary":"Curium Consolidates New Biopharma Business and Sets Up Global Headquarters in Boston, Massachusetts - GlobeNewswire","headline":"Curium Consolidates New Biopharma Business and Sets Up Global Headquarters in Boston, Massachusetts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNOVBSZVRrZGhUUkdMZWk5QUJObkRhSFVCVFpoV1NCOFY1eVNXWWg3TjhiRjRDbHVPNlFDenVzM0JYdEdaM0tOUngzemxhQW5KMjlvWG5uMUR0NmtUTDRwOHhYb1Q2empUVzZ3X2RtZUhvQlVWYVlPOEsyTnhMeFZVbWpLWnJ6VmZuMkpnazVBV3NBMm0wa0dKRl9wRS1DV21LajNQMEVMamgzcm8zcUxqZmVNZnlocnFZaUxtd0pJS255Sk5sS0RhdURzaW1fcjkzWlpCOFBWYUc3VjloWVRhNUszVExTQTJyakg2d1g3ZlFfVXc?oc=5","date":"2025-02-24","type":"pipeline","source":"Cardiovascular Business","summary":"Continuation of 99mTc-PYP shortage prompts need for alternative cardiac amyloidosis imaging - Cardiovascular Business","headline":"Continuation of 99mTc-PYP shortage prompts need for alternative cardiac amyloidosis imaging","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQTXpxazMxMVBSVDRCazlPMFZmb0dMUHBwYUduSlIzR2lHRmdBclliajJiRml2c1g2ZUV3YThUV01rLVBhZWZGRDZha3lGemNWWHFWV0N5TzVFUXhLX0VVbGN4N0NYckdsVExSTFVrcG1rbTdJSXJxUVZLc1ctZjNHVThlMUY5RkxaUFZsUWtIOGU0RGprZ3dhS2twbFZBejlhQnRUVm1ZRUwyWk01?oc=5","date":"2024-11-04","type":"patent","source":"Fierce Pharma","summary":"In defense of radioligand therapies, Novartis fired off patent lawsuits against Lilly and other rivals - Fierce Pharma","headline":"In defense of radioligand therapies, Novartis fired off patent lawsuits against Lilly and other rivals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPN0hNQkNaSE5SbGtYTDRNbmY4OWV3ODJlb1ZFZW1jWW5zSklGWEtDOS1mYUJFUHdWMGxyLTN2ZDR4aFB2c0tLNnFRQ2lZTGJ6aGViRWRWT0lPRVctLVBGYzEzdFU5RTFsLWtoUW1CU2ZqUkMzQnFNVTk3bmxZZWhCQnhaMW1wdkhrSENYWC1VaUQ2a1V1NW1CYWJMbmhpUU1TenY3NjVRWW5JZUF3d25WaDZKZmhQMVN2UjF6RTluaUY4dVJGelo3N2huRlJ2b1BKRHpIVXltc3dLODNPNkt0bGN3RGg4WGdtTjU4QUdDNm9rTGhtVVd3SjB1QzdPemNKbXMzV3pSN19handVUjgzN0laVVpQNFF2N2p4dWtvcE8zd01hZmJzekZvMDA4YkVjNFlB?oc=5","date":"2024-07-09","type":"pipeline","source":"PR Newswire","summary":"Radioligand Therapies Market to Show Immense Growth by 2034, Predicts DelveInsight | Key Companies - Curium US, Eli Lilly, Point Biopharma, Fusion, Astrazeneca - PR Newswire","headline":"Radioligand Therapies Market to Show Immense Growth by 2034, Predicts DelveInsight | Key Companies - Curium US, Eli Lill","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNdkQ3TGgteThUVkJLRGlLNHJNWGhvbUdZeXc1VnNTWENrc2hKbzVlZmJVQnlMMEtLeXNtWEl5T1VWb0lkOU8zelhpVTl0SGNxTjhNUnlRMjN5S1AwZ2tMdEdGQl9kdmVRRmRjRUxsOGowcW9yQmp4YmlfTXdZMWFmZGpfT3ZXdw?oc=5","date":"2022-01-24","type":"pipeline","source":"Yahoo Finance","summary":"Curium to become major player in the supply on non carrier added Lu-177 - Yahoo Finance","headline":"Curium to become major player in the supply on non carrier added Lu-177","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}